Foundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required

Updated August 14, 2026: Foundayo (orforglipron) is a non-peptide oral GLP-1 medication for weight management, FDA-approved April 1, 2026. It produced 12.4% body weight loss over 72 weeks in the ATTAIN-1 Phase 3 trial. LillyDirect Self Pay lists $149/month at 0.8 mg; $199 at 2.5 mg; $299 at 5.5 mg or 9 mg; and $299 at 14.5 mg or 17.2 mg only when refilled within 45 days, otherwise $349 ($649/month WAC list price). The ACHIEVE-4 cardiovascular safety trial in adults with type 2 diabetes met its MACE-4 noninferiority endpoint and reported a 57% reduction in all-cause mortality as a secondary finding (HR 0.43; nominal P=.002); that secondary result is not proof of the same mortality effect in a general obesity population. Foundayo has no food or water restrictions and is taken once daily as prescribed.

Quick answer: should you choose Foundayo?

• •YES, if you're needle-phobic or travel frequently: No injections, no fasting, no fridge required
• •YES, if you want the newest GLP-1: FDA-approved April 1, 2026, youngest approval on the market
• •COMPARE THE FULL PRICE, if cost matters: Foundayo starts at $149/mo but rises by dose and refill timing; NovoCare Wegovy pill also starts at $149/mo, while the pen is $199/mo for the first two low-dose fills before rising to $349/mo at standard strengths ($399 HD). Compare the prescribed strength and checkout total, not Foundayo's $649 list price against another drug's cash-pay offer
• •NO, if max weight loss is the goal: Tirzepatide (Zepbound) produces 20.9% vs Foundayo's 12.4%, see Wegovy vs Zepbound. For injectable semaglutide results month by month: semaglutide before and after timeline (14.9-20.7% depending on dose)
• •MAYBE, if you're choosing between pills: Oral Wegovy produced 16.6% in OASIS vs Foundayo's 12.4% in ATTAIN-1, separate trials rather than a head-to-head study. Both cash-pay floors start at $149/mo, while dosing and refill conditions differ. Compare: Foundayo vs Wegovy Pill · All oral GLP-1 pill options compared

This guide covers orforglipron's non-peptide mechanism (why it survives stomach acid without SNAC), the ATTAIN-1 and ACHIEVE-1 trial data, exact side effect percentages, the full dosing schedule, pricing across channels, and how it compares to Wegovy and Zepbound. Compare Foundayo against all options in our provider rankings or use the cost calculator.

What Is Foundayo and How Is It Different?

Foundayo's active ingredient, orforglipron, is a non-peptide small molecule GLP-1 receptor agonist. Every other GLP-1 on the market, Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, is based on modified peptides (synthetic versions of natural hormones). This matters for a practical reason:

Peptides get destroyed in the stomach. That's why most GLP-1s are injections, and why oral semaglutide (Wegovy pill, Rybelsus) requires a special absorption enhancer called SNAC, which forces you to take it on an empty stomach with no more than 4 oz of plain water, then wait 30 minutes before eating or drinking anything else.

Orforglipron is not a peptide, so it survives the stomach on its own. No absorption enhancer needed. No food restrictions. No water restrictions. Take it any time of day, with or without meals. This is Foundayo's single biggest practical advantage over every other GLP-1 option.

Clinical Trial Results: How Much Weight Does Foundayo Help You Lose?

Foundayo was studied in the ATTAIN clinical trial program. The pivotal trial for obesity was ATTAIN-1, published in the New England Journal of Medicine.

ATTAIN-1 results (3,127 adults with obesity, 72 weeks):

For context, the STEP 1 trial showed injectable semaglutide (Wegovy 2.4mg) produced 14.9% weight loss at 68 weeks, and SURMOUNT-1 showed tirzepatide (Zepbound 15mg) produced 22.5% at 72 weeks. Foundayo's 11-12% falls below both, but it is a pill with zero dosing restrictions, which is a meaningful tradeoff for many patients.

ATTAIN-2 studied Foundayo in patients with obesity AND type 2 diabetes: 10.5% mean weight loss (22.9 lbs) plus a 1.8% reduction in HbA1c at the highest dose.

ATTAIN-MAINTAIN (the first study of its kind) showed that patients who switched from injectable semaglutide or tirzepatide to oral Foundayo maintained most of their weight loss, with modest regain of approximately 5 kg compared to 9 kg on placebo. This positions Foundayo as a viable oral maintenance option after initial injectable treatment.

What Are Foundayo's Side Effects?

Like all GLP-1 medications, Foundayo's most common side effects are gastrointestinal. The rates below are from the official FDA prescribing information:

Discontinuation rates due to side effects: 10% at the 17.2 mg dose vs 3.2% on placebo. Most GI side effects were mild to moderate, occurred during dose escalation, and decreased over time.

Boxed warning: Like all GLP-1 medications, Foundayo carries a boxed warning about thyroid C-cell tumors observed in rodent studies with other GLP-1 agonists. Notably, orforglipron itself did not produce tumors in rodents (it is not pharmacologically active in rodent GLP-1 receptors), but the class warning is required. Foundayo is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Five mild cases of pancreatitis were confirmed across the ATTAIN-1 trial. Patients should report severe, persistent abdominal pain to their healthcare provider immediately.

Foundayo Dosing Schedule

Foundayo uses a gradual titration schedule with six dose levels. Each step lasts at least 30 days to minimize GI side effects:

Total time to reach maximum dose: approximately 5 months. Your provider may adjust the pace based on your tolerability and response. Some patients achieve meaningful weight loss at the 9 mg or 14.5 mg dose and don't need to escalate to 17.2 mg.

How Much Does Foundayo Cost per Month?

Foundayo self-pay runs $149 to $349 a month depending on dose and refill timing. Eligible commercially insured patients may pay as little as $25 under the Lilly savings-card terms, and eligible Medicare Part D patients pay a $50 Bridge copay.

Foundayo pricing is structured by dose level, with self-pay prices available through LillyDirect:

Lilly savings card: Covers up to $100/month for a 1-month fill, $200 for 2-month, $300 for 3-month. Annual cap of $1,000. Expires December 31, 2026. Available to commercially insured patients. Check eligibility at foundayo.lilly.com.

For comparison, NovoCare lists oral Wegovy from $149/month and the pen at $199/month for the first two low-dose fills, then $349/month at standard strengths ($399 HD). Foundayo's higher strengths cost $299 only when the 45-day refill condition is met at 14.5 or 17.2 mg; otherwise they cost $349. See our full cost comparison across 54 providers for provider program fees and other options.

How Does Foundayo Compare to Other GLP-1 Medications?

Choose Foundayo if: Dosing convenience is your top priority. You want a pill you can take any time without food/water restrictions. You're switching from an injectable and want an oral maintenance option (ATTAIN-MAINTAIN trial supports this). You prefer a Lilly product and want to stay in their ecosystem (Zepbound → Foundayo step-down).

Choose Wegovy (oral or injection) if: Maximum weight loss matters most to you. You want fewer GI side effects with the pill form. Note: Both semaglutide (SELECT trial, obesity with established CVD) and orforglipron (ACHIEVE-4 trial, T2D) have demonstrated cardiovascular outcome benefits, SELECT specifically studied high-CV-risk weight loss patients while ACHIEVE-4 studied T2D. Discuss your cardiovascular history with your provider when choosing between the two.

Choose Zepbound if: You want the highest weight loss possible (20%+) and don't mind a weekly injection. The dual GIP + GLP-1 mechanism produces meaningfully more weight loss than any single-agonist option.

For a deeper comparison of the two oral options, see our Foundayo vs Wegovy Pill analysis. For a broader drug comparison, read Semaglutide vs Tirzepatide.

Where to Get Foundayo Online

As of April 2026, Foundayo is broadly available across LillyDirect, telehealth platforms, and retail pharmacies:

LillyDirect Self Pay: Eli Lilly's direct-to-patient platform has accepted Foundayo prescriptions since April 6, 2026. Pricing is $149/month at 0.8 mg, $199 at 2.5 mg, $299 at 5.5 mg or 9 mg, and $299 at 14.5 mg or 17.2 mg only when refilled within 45 days, otherwise $349. Visit LillyDirect.

Telehealth platforms listed Foundayo in April 2026: Ro, Sesame Care, Shed, Found, and Lemonaid Health. Their program starting prices can include membership or consultation services and should not be read as the Foundayo medication price for every dose. Confirm the medication strength, provider fee, refill condition, and all-in checkout total. For the ordering flow, see our Foundayo walkthrough.

Retail pharmacies: Amazon Pharmacy (same-day delivery, LillyDirect-integrated), GoodRx, CVS, Walgreens, and most major independent pharmacies carry Foundayo as of April 2026.

Foundayo Eligibility: Who Qualifies?

Foundayo is FDA-approved for adults who meet the same criteria as other weight loss GLP-1 medications:

• •BMI of 30 or higher (obesity), OR
• •BMI of 27 or higher with at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, obstructive sleep apnea, NAFLD/NASH, or PCOS
• •Must be 18 or older (not yet approved for adolescents, unlike Wegovy)
• •Use in combination with a reduced-calorie diet and increased physical activity

Not sure if you qualify? Use our GLP-1 eligibility checker for a quick preliminary assessment. A healthcare provider will make the final determination based on your complete medical history.

Frequently Asked Questions About Foundayo

Is Foundayo the same as Zepbound?

No. Both are made by Eli Lilly, but they are different drugs. Zepbound contains tirzepatide (a dual GIP + GLP-1 agonist given as a weekly injection). Foundayo contains orforglipron (a GLP-1-only agonist taken as a daily pill). Zepbound produces greater weight loss (20%+ vs 11-12%), but Foundayo offers the convenience of an oral pill with no food restrictions.

Can I switch from Zepbound or Wegovy to Foundayo?

Yes. The ATTAIN-MAINTAIN trial specifically studied patients switching from injectable semaglutide or tirzepatide to Foundayo. Patients maintained most of their weight loss, with modest regain of about 5 kg over 52 weeks (vs 9 kg regain on placebo). Discuss the transition plan with your prescribing provider.

Does insurance cover Foundayo?

Coverage is still rolling out as of April 2026. Commercial insurance plans are in the process of adding Foundayo to formularies. Lilly offers a savings card that brings commercially insured patients down to as low as $25/month. Medicare Part D is expected to cover Foundayo starting with the GLP-1 Bridge program in July 2026 at approximately $50/month copay. Use our insurance coverage lookup tool to check your specific plan.

Why are Foundayo's side effects higher than Wegovy pill?

Orforglipron is a partial agonist with a different signaling profile than semaglutide at the GLP-1 receptor. It favors cAMP signaling over beta-arrestin recruitment, which may partly explain the higher GI rates. That said, most side effects are mild to moderate, occur during dose escalation, and decrease over time. The 10% discontinuation rate at the highest dose is in line with other GLP-1 medications.

How long until I see results on Foundayo?

Based on clinical trial data, meaningful weight loss begins during the dose escalation phase (months 2-3) and continues to increase through month 6-8. The full titration to the maximum 17.2 mg dose takes approximately 5 months. Most patients in ATTAIN-1 who completed the full 72-week treatment period achieved 10%+ body weight loss.

The Bottom Line on Foundayo

Foundayo fills a real gap in the GLP-1 landscape: it's the only weight loss pill you can take without thinking about food timing, water restrictions, or injection anxiety. The tradeoff is lower weight loss (~12%) compared to injectable options (~15-23%) and slightly more GI side effects than oral semaglutide.

For patients who have been on the fence about starting a GLP-1 because they don't want injections or can't deal with oral semaglutide's rigid dosing rules, Foundayo removes those barriers. For patients already on injectables who want to transition to a pill for long-term maintenance, the ATTAIN-MAINTAIN data supports that path.

At $299/month self-pay for maintenance doses (or as low as $25/month with commercial insurance + savings card), pricing is competitive with other brand-name options. The real question is whether your insurance will cover it yet, and that's a moving target as formularies update through mid-2026.

Not sure which GLP-1 is right for you? Our provider match quiz can pair you with the right program in under 2 minutes, or check the full provider rankings to compare all 54 telehealth options side-by-side.

Sources